CD8A and neoplasm: Most MSI-H tumors predominantly align with the CMS1 category, characterized by a high mutational load, an immunogenic tumor environment, the presence of specific TILs (e.g., CD8+ cytotoxic T lymphocytes, CD4+ T helper 1 cells and natural killer cells), and an excellent prognosis in early stage CRC [37].